C3L-02219
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77.60985626
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- IL6_JAK_STAT3_SIGNALING+0.460
- INTERFERON_GAMMA_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.420
- INFLAMMATORY_RESPONSE+0.380
- KRAS_SIGNALING_UP+0.340
- TNFA_SIGNALING_VIA_NFKB+0.320
- HYPOXIA+0.290
- COAGULATION+0.270
- COMPLEMENT+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.490
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.450
- MITOTIC_SPINDLE-0.350
- MYC_TARGETS_V1-0.290
- PANCREAS_BETA_CELLS-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.230
- MTORC1_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.180
- APICAL_SURFACE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b1dde645-b48d-44e0-9fe0-2af02470ffb5 | — | — | 0.874 |
| 2 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.864 |
| 3 | ERR2208891 | — | — | 0.861 |
| 4 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.860 |
| 5 | TCGA-97-8175-01A-11R-2287-07 | — | cohortA1 | 0.856 |
| 6 | SRR8943021 | — | — | 0.849 |
| 7 | SRR13780263 | — | cohortMD2 | 0.846 |
| 8 | TCGA-DQ-5625-01A-01R-1873-07 | — | — | 0.846 |
| 9 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.841 |
| 10 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |